Dyne Therapeutics, Inc.
DYN
$9.57
-$0.48-4.78%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.93M | 15.30M | 12.86M | 9.70M | 24.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.37M | 97.11M | 105.66M | 71.96M | 69.16M |
| Operating Income | -122.37M | -97.11M | -105.66M | -71.96M | -69.16M |
| Income Before Tax | -115.36M | -89.54M | -97.13M | -65.10M | -65.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -115.36M | -89.54M | -97.13M | -65.10M | -65.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -115.36M | -89.54M | -97.13M | -65.10M | -65.65M |
| EBIT | -122.37M | -97.11M | -105.66M | -71.96M | -69.16M |
| EBITDA | -121.87M | -96.66M | -105.22M | -71.56M | -68.77M |
| EPS Basic | -1.05 | -0.88 | -0.96 | -0.70 | -0.81 |
| Normalized Basic EPS | -0.66 | -0.55 | -0.60 | -0.44 | -0.51 |
| EPS Diluted | -1.05 | -0.88 | -0.96 | -0.70 | -0.81 |
| Normalized Diluted EPS | -0.66 | -0.55 | -0.60 | -0.44 | -0.51 |
| Average Basic Shares Outstanding | 109.91M | 101.98M | 100.88M | 92.51M | 81.04M |
| Average Diluted Shares Outstanding | 109.91M | 101.98M | 100.88M | 92.51M | 81.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |